A predictive model combining fecal Calgranulin B and fecal occult blood tests can improve the diagnosis of colorectal cancer

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Kim, Byung Chang ^a   Joo, Jungnam ^a   Chang, Hee Jin ^a   Yeo, Hyun Yang ^a   Yoo, Byong Chul ^a   Park, Boram ^a   Park, Ji Won ^a,b   Sohn, Dae Kyung ^a   Hong, Chang Won ^a   Han, Kyung Su ^a  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN B;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER STAGING; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FECES ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; OCCULT BLOOD TEST; PREDICTION; PROCESS DEVELOPMENT; PROSPECTIVE STUDY; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; WESTERN BLOTTING; CHEMISTRY; COLORECTAL NEOPLASMS; FECES; METABOLISM; OCCULT BLOOD; THEORETICAL MODEL;

BLOTTING, WESTERN; CALGRANULIN B; COLORECTAL NEOPLASMS; FECES; HUMANS; MODELS, THEORETICAL; OCCULT BLOOD;

EID: 84907104284     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106182     Document Type: Article

References (34)

1. Davies RJ, Miller R, Coleman N (2005) Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 5: 199-209.
2. Jung KW, Won YJ, Park S, Kong HJ, Sung J, et al. (2009) Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 24: 995-1003.
3. Rhodes JM (2000) Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, The Royal College of Physicians, and The Association of Coloproctology of Great Britain and Ireland. Gut 46: 746-748.
4. Ahlquist DA, Gilbert JA (1996) Stool markers for colorectal cancer screening: future considerations. Dig Dis 14: 132-144.
5. Osborn NK, Ahlquist DA (2005) Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128: 192-206.
6. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
7. Yoo BC, Shin YK, Lim SB, Hong SH, Jeong SY, et al. (2008) Evaluation of calgranulin B in stools from the patients with colorectal cancer. Dis Colon Rectum 51: 1703-1709.
8. Foell D, Wittkowski H, Ren Z, Turton J, Pang G, et al. (2008) Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. The Journal of pathology 216: 183-192.
9. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, et al. (2001) Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49: 402-408.
10. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, et al. (2004) Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 53: 1329-1333.
11. Foell D, Wittkowski H, Roth J (2009) Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 58: 859-868.
12. Flahault A, Cadilhac M, Thomas G (2005) Sample size calculation should be performed for design accuracy in diagnostic test studies. Journal of clinical epidemiology 58: 859-862.
13. Hamilton SR, Aaltonen LA (2000) Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; Oxford: Oxford University Press [distributor]. 314 p.
14. Greene FL (2002) AJCC cancer staging manual. New York; London: Springer. xiv, 421 p.
15. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, et al. (2000) Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. The New England journal of medicine 343: 162-168.
16. Iman RL, Conover WJ (1979) The use of the rank transform in regression. Technometrics 21: 499-509.
17. Simon R (2003) Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. British journal of cancer 89: 1599-1604.
18. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Statistics in medicine 27: 157-172.
19. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
20. Allison JE, Feldman R, Tekawa IS (1990) Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting. Ann Intern Med 112: 328-333.
21. Ahlquist DA (1997) Fecal occult blood testing for colorectal cancer. Can we afford to do this? Gastroenterol Clin North Am 26: 41-55.
22. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. The New England journal of medicine 328: 1365-1371.
23. St John DJ, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA (1992) Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia. Ann Intern Med 117: 376-382.
24. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, et al. (2000) Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 46: 795-800.
25. Shitrit AB, Braverman D, Stankiewics H, Shitrit D, Peled N, et al. (2007) Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum 50: 2188-2193.
26. Dabritz J, Musci J, Foell D (2014) Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World journal of gastroenterology 20: 363-375.
27. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, et al. (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMNelastase, CRP, and clinical indices. The American journal of gastroenterology 103: 162-169.
28. Schroder O, Naumann M, Shastri Y, Povse N, Stein J (2007) Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Alimentary pharmacology & therapeutics 26: 1035-1042.
29. Karl J, Wild N, Tacke M, Andres H, Garczarek U, et al. (2008) Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin Gastroenterol Hepatol 6: 1122-1128.
30. Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, et al. (2009) Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 18: 1888-1893.
31. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, et al. (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102: 7677-7682.
32. Greenland P, O'Malley PG (2005) When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Archives of internal medicine 165: 2454-2456.
33. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. American journal of epidemiology 159: 882-890.
34. Ware JH (2006) The limitations of risk factors as prognostic tools. The New England journal of medicine 355: 2615-2617.